APPLICATION OF HEMOFILTERCYTOLOGICAL TESTS FOR ASSIGNING ADJUVANT POLYCHEMOTHERAPHY TO CANCER PATIENTS AND EVALUATING ITS EFFICACY

Article Sidebar

PDF (Russian) HTML (Russian)
Issue:
Section:
ORIGINAL ARTICLES
Published:
2022-03-21
DOI:
https://doi.org/10.24412/2687-0053-2022-1-20-24

Main Article Content

Георгий Цыренович Дамбаев
Siberian State Medical University image/svg+xml
Анатолий Агванович Чимитов
Buryat State University, Ulan-Ude, Republic of Buryatia
Александр Федорович Лазарев
Altai State Medical University, Barnaul
Лувсанням Лхагва
Mongolian Academy of Medical Sciences, Ulaanbaatar
Александр Сергеевич Степанов
Mirny Central Regional Hospital, Republic of Sakha Yakutia

Abstract

Hemofiltercytological venous blood tests for patients radically operated on for colon cancer reveals circulating tumor cells (CTCs) in the early postoperative period. Their results serve as an indication for assigning adjuvant polychemotherapy to post-operative patients. The repeated hemofiltrocytological test on the intensity of CTCs damages and decrease in their number makes it possible to assess the quality and completeness of adjuvant polychemotherapy.

Keywords

hemofiltrocytological test, adjuvant polychemotherapy, circulating cancer cells

Author Biographies

Георгий Цыренович Дамбаев,

Georgy Ts. Dambaev
MD, PhD, professor, Corresponding Member of the Russian Academy of Sciences, Honored Researcher of Russian Federation

Head of the Hospital Surgery Department with a course of cardiovascular surgery

Анатолий Агванович Чимитов,
candidate of medical sciences, assistant, department of human anatomy and physiology
Александр Федорович Лазарев,
doctor of medical sciences, professor, head of the department of oncology
Лувсанням Лхагва,
doctor of medical sciences, professor, academician, vice-president
Александр Сергеевич Степанов,
oncologist

Article Details

Information about financing and conflict of interests

The study had no sponsorship.
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
© Георгий Цыренович Дамбаев, Анатолий Агванович Чимитов, Александр Федорович Лазарев, Лувсанням Лхагва, Александр Сергеевич Степанов, 2022


Creative Commons License  This work is licensed under a Creative Commons Attribution 4.0 License.

How to Cite

Дамбаев, Г. Ц., Чимитов, А. А., Лазарев, А. Ф., Лхагва, Л., & Степанов, А. С. (2022). APPLICATION OF HEMOFILTERCYTOLOGICAL TESTS FOR ASSIGNING ADJUVANT POLYCHEMOTHERAPHY TO CANCER PATIENTS AND EVALUATING ITS EFFICACY. Medicine in Kuzbass, 21(1), 20-24. https://doi.org/10.24412/2687-0053-2022-1-20-24

References

Prophets VV, Vlasov OA, Tupitsyn NN. The current state of the problem of treatment and prognosis of colorectal cancer. Oncology issues. 2014; 60: 28-33. Russian (Пророков В.В., Власов О.А., Тупицын Н.Н. Современное состояние проблемы лечения и прогноза колоректального рака //Вопросы онкологии. 2014. Т. 60. С. 28-33.)

Garin AM, Bazin IS. Reference guide to drug therapy of solid tumors. M.: MAX Press, 2010. 368 p. Russian (Гарин А.М., Базин И.С. Справочное руководство по лекарственной терапии солидных опухолей. М.: МАКС Пресс. 2010. 368 с.)

Bzhadug ОВ, Tjulandin SA, Grivtsova LYu, et al. The prognostic value of circulating tumor cells in blood of patients with advanced breast cancer. Haematopoesis Immunology. 2007; 4: 73-101

Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Eng. J Med. 2004; 351(8): 781-791

Cohen SJ, Punt CJ, Lannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008; 26(19): 3213-3221

De Bono JS, Tolcher AW, Rowinsky EK. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. Semin Oncol. 2003; 30(Suppl. 16): 79-92

Downloads

Download data is not yet available.

Most read articles by the same author(s)